The July 1 quarterly HCPCS Level II update includes several drug/biological code changes, according to an AAPC release.
Effective July 1, the HCPCS Level II code J7184 will be replaced with Q2041 Injection, Von Willebrand factor complex (human), Wilate, per 100 IU VWF RCo. This code describes Wilate for intravenous injection for spontaneous or trauma-induced bleeding in patients with von Willebrand Disease.
There are also three new Q codes payable for Medicare starting on or after July 1:
• Q2042 Injection, hydroxyprogesterone caproate, 1 mg
The FDA approved hydroxyprogesterone caproate, a synthetic steroid hormone marked as Makena, on Feb. 3, 2011. The drug is approved for prevention of preterm delivery in women with a history of preterm delivery.
• Q2043 Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion
Sipuleucel-T (Provenge) is a therapeutic cancer vaccine. The drug was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
• Q2044 Injection, belimumab, 10 mg
Belimumab was approved in March 2011 for treatment of systemtic lupus erthmatosis. The drug is marked as Benlysta and is investigational for other autoimmune diseases.
Read the AAPC release on HCPCS updates.
Related Articles on Billing, Coding and Collections:
Orthopedic Coding: 4 Tips for Knee Injuries and Conditions
Physician Organizations Suggest Alternatives to SGR
CMS Implements New Policy for Modifier KY Starting Oct. 1
Effective July 1, the HCPCS Level II code J7184 will be replaced with Q2041 Injection, Von Willebrand factor complex (human), Wilate, per 100 IU VWF RCo. This code describes Wilate for intravenous injection for spontaneous or trauma-induced bleeding in patients with von Willebrand Disease.
There are also three new Q codes payable for Medicare starting on or after July 1:
• Q2042 Injection, hydroxyprogesterone caproate, 1 mg
The FDA approved hydroxyprogesterone caproate, a synthetic steroid hormone marked as Makena, on Feb. 3, 2011. The drug is approved for prevention of preterm delivery in women with a history of preterm delivery.
• Q2043 Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion
Sipuleucel-T (Provenge) is a therapeutic cancer vaccine. The drug was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
• Q2044 Injection, belimumab, 10 mg
Belimumab was approved in March 2011 for treatment of systemtic lupus erthmatosis. The drug is marked as Benlysta and is investigational for other autoimmune diseases.
Read the AAPC release on HCPCS updates.
Related Articles on Billing, Coding and Collections:
Orthopedic Coding: 4 Tips for Knee Injuries and Conditions
Physician Organizations Suggest Alternatives to SGR
CMS Implements New Policy for Modifier KY Starting Oct. 1